Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
6.1
4.3
Journals
Pharmaceuticals
Special Issues
Modern Approach to Neuroendocrine Neoplasms Diagnosis and Treatment
share announcement

Modern Approach to Neuroendocrine Neoplasms Diagnosis and Treatment

A special issue of Pharmaceuticals (ISSN 1424-8247). This special issue belongs to the section "Medicinal Chemistry".

Deadline for manuscript submissions: closed (25 January 2025) | Viewed by 4244

Special Issue Editors

Prof. Dr. Marek Saracyn

E-Mail Website
Guest Editor
Department of Endocrinology and Radioisotope Therapy, Military Institute of Medicine-National Research Institute, 04-141 Warsaw, Poland
Interests: endocrinology; neuroendocrine neoplasms
Dr. Adam Daniel Durma

E-Mail Website
Guest Editor
Department of Endocrinology and Radioisotope Therapy, Military Institute of Medicine-National Research Institute, 04-141 Warsaw, Poland
Interests: neuroendocrine neoplasms; andrology

Special Issue Information

Dear Colleagues,

The diagnosis and treatment of neuroendocrine neoplasms (NENs) remains a challenging issue, mainly due to the heterogeneous character of the disease and variations in the treatment response. Current treatment options not only include classic surgery, somatostatin analogs, radioligand therapy, chemotherapy and targeted therapy, but also careful observation or minimally invasive interventions.

Hence, we would like to invite all researchers working in the field of neuroendocrine neoplasms to contribute to this Special Issue of Pharmaceuticals, entitled "Modern Approaches to the Diagnosis and Treatment of Neuroendocrine Neoplasms", and share their experiences, results, or insights into the disease.

Pharmaceuticals offers the publication of high-quality papers in the field, and currently boasts a journal impact factor of 4.6.

We hope that the given deadline—30 June 2024—will be acceptable for all those interested in publishing in this Special Issue. However, an extension of the deadline for the preparation of high-value publications is possible.

Prof. Dr. Marek Saracyn
Dr. Adam Daniel Durma
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • neuroendocrine neoplasms (NENs)
  • neuroendocrine tumors (NETs)
  • non-invasive interventions
  • NEN surgery
  • somatostatin analogs
  • radioligand therapy (RLT, PRRT)
  • NEN targeted therapy
  • NEN chemotherapy
  • NEN epidemiology
  • NEN treatment complications
  • [68Ga]Ga-PET/CT
  • [18F]FDG- PET/CT
  • [99mTc]-scintigraphy

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Review

Jump to: Other

22 pages, 6031 KiB  
Review
The Management of Phaeochromocytomas and Paragangliomas in the Era of Precision Medicine: Where Are We Now? Evidence-Based Systemic Treatment Options and Future Cluster Oriented Perspectives
by Alessandra Bracigliano, Antonella Lucia Marretta, Luigi Pio Guerrera, Roberto Simioli, Ottavia Clemente, Vincenza Granata, Anita Minopoli, Giuseppina Della Vittoria Scarpati, Fernanda Picozzi, Lucia Cannella, Antonio Pizzolorusso, Francesca Di Gennaro, Roberto Tafuto, Maria Rosaria Sarno, Ernesta Cavalcanti, Dario Ribera and Salvatore Tafuto
Pharmaceuticals 2024, 17(3), 354; https://doi.org/10.3390/ph17030354 - 8 Mar 2024
Cited by 7 | Viewed by 2746
Abstract
Pheochromocytomas (PCCs) and Paragangliomas (PGLs), commonly known as PPGLs to include both entities, are rare neuroendocrine tumors that may arise in the context of hereditary syndromes or be sporadic. However, even among sporadic PPGLs, identifiable somatic alterations in at least one of the [...] Read more.
Pheochromocytomas (PCCs) and Paragangliomas (PGLs), commonly known as PPGLs to include both entities, are rare neuroendocrine tumors that may arise in the context of hereditary syndromes or be sporadic. However, even among sporadic PPGLs, identifiable somatic alterations in at least one of the known susceptibility genes can be detected. Therefore, about 3/4 of all PPGL patients can be assigned to one of the three molecular clusters that have been identified in the last years with difference in the underlying pathogenetic mechanisms, biochemical phenotype, metastatic potential, and prognosis. While surgery represents the mainstay of treatment for localized PPGLs, several therapeutic options are available in advanced and/or metastatic setting. However, only few of them hinge upon prospective data and a cluster-oriented approach has not yet been established. In order to render management even more personalized and improve the prognosis of this molecularly complex disease, it is undoubtable that genetic testing for germline mutations as well as genome profiling for somatic mutations, where available, must be improved and become standard practice. This review summarizes the current evidence regarding diagnosis and treatment of PPGLs, supporting the need of a more cluster-specific approach in clinical practice. Full article
(This article belongs to the Special Issue Modern Approach to Neuroendocrine Neoplasms Diagnosis and Treatment)
►▼ Show Figures

Figure 1

Other

Jump to: Review

26 pages, 1442 KiB  
Systematic Review
Theranostics in Renal Cell Carcinoma—A Step Towards New Opportunities or a Dead End—A Systematic Review
by Katarzyna Jóźwik-Plebanek, Marek Saracyn, Maciej Kołodziej, Olga Kamińska, Adam Daniel Durma, Weronika Mądra, Katarzyna Agnieszka Gniadek-Olejniczak, Marek Dedecjus, Jakub Kucharz, Rafał Stec and Grzegorz Kamiński
Pharmaceuticals 2024, 17(12), 1721; https://doi.org/10.3390/ph17121721 - 19 Dec 2024
Cited by 1 | Viewed by 1015
Abstract
Background: Renal cell carcinoma is one of the most aggressive urogenital malignancies, with an increasing number of cases worldwide. The majority of cases are diagnosed at an advanced stage, as this form of growth is typically silent. An accurate evaluation of the extent [...] Read more.
Background: Renal cell carcinoma is one of the most aggressive urogenital malignancies, with an increasing number of cases worldwide. The majority of cases are diagnosed at an advanced stage, as this form of growth is typically silent. An accurate evaluation of the extent of the disease is crucial for selecting the most appropriate treatment approach. Nuclear medicine imaging is increasingly being applied in oncological diagnostics, prompting ongoing research into renal cell carcinoma markers that could serve as a foundation for theranostic approaches in this disease. Positron emission tomography/computed tomography imaging with prostate-specific membrane antigen (PSMA) ligands has already demonstrated successful utility in diagnosis of other cancers, including prostate cancer and gliomas. Emerging evidence of high sensitivity and specificity in detecting renal cell carcinoma lesions provides a suitable foundation for its application in both the diagnosis and subsequent management of this malignancy. Methods: This systematic review synthesizes the current scientific evidence on the molecular imaging of renal cell carcinoma using PSMA ligands, emphasizing the potential future applications of this imaging marker in theranostic approaches. Results and Conclusions: Based on a systematic review of the literature, it appears that PET/CT with PSMA ligands has the potential to surpass traditional imaging techniques in diagnostic accuracy while also providing valuable prognostic information. Full article
(This article belongs to the Special Issue Modern Approach to Neuroendocrine Neoplasms Diagnosis and Treatment)
►▼ Show Figures

Graphical abstract

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop